3Blondeau JM, Felmingham D. Activity of moxifloxacin against Community RTIs [ J ]. Clin Drug Invest, 1999,189 (1) :57.
4Gulley CN, Lacy MK, Klutman N, et al, moxifloxacin: Clinical efficacy and safety [ J ]. Am J Health Syst Phamo ,2001,58 (5) :379.
5Koch H,Lanclen H,Stauch K. Once-duity, moxifloxacin thenrpy for Community - acquired pneumonia in general practice evrdence from a post-marketing surveillance study of 1 467 patients [ J ]. Clin Drug lnvestig, 2004, 24 (8) :441.
6Wilson R, Kubin R, Ballin I, et al. Five day moxifloxacin therapy compared with 7 day clarthromycin therapy for the theatment of acute exacerbations of chronic bronchitis [ J ]. J Antimicrob Chemother, 1999,44 ( 4 ) : 501.
7Wilson R, Allegra, Huchon G, et al. Short - term and longterm outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronicbronchitis [ J ]. Chest, 2004,125 ( 2 ) :953.
8Kniazkin IV, Aleksandrov VP, Zeziulin PN, et al. Use of avelox in treating urogenital infections inmen [ J ]. Urologiia ,2002,5:6.
9Burke T, Villanueva C, Mariano H, et al. Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis [ J ]. Clin Ther, 1999, 21 (10) : 1664.
10Lipsky BA, Giordano P, Choudhri S, et al. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin - tazobactam / amoxicillin - clavulanate [ J ]. Antimicrob Chemother, 2007,60(2) ; 370.
